Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Incidence, Prevalence, and Mortality Rate of Gastrointestinal Cancer in Isfahan, Iran: Application of the MIAMOD Method

  • Moradpour, Farhad (Social Determinants of Health Research Center, Kurdistan University of Medical Sciences) ;
  • Gholami, Ali (Department of Public Health, School of Public Health, Neyshabur University of Medical Sciences) ;
  • Salehi, Mohammad (Department of Biostatistics, Faculty of Medicine, Shiraz University of Medical Sciences) ;
  • Mansori, Kamiar (Department of Epidemiology, School of Public Health, Shahid Beheshti University of Medical Sciences) ;
  • Maracy, Mohammad Reza (Department of Epidemiology and Biostatistics, Isfahan University of Medical Science) ;
  • Javanmardi, Setareh (Department of Anatomical Sciences, Faculty of Nursing and Midwifery, Kermanshah University of Medical Sciences) ;
  • Rajabi, Abdolhalim (Iran University of Medical Sciences) ;
  • Moradi, Yousef (Iran University of Medical Sciences) ;
  • Khodadost, Mahmod (Iran University of Medical Sciences)
  • Published : 2016.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

Gastrointestinal cancers remain the most prevalent cancers in many developing countries such as Iran. The aim of this study was to estimate incidence, prevalence and mortality, as well as time trends for gastrointestinal cancers in Isfahan province of Iran for the period 2001 to 2010 and to project these estimates to the year 2020. Estimates were driven by applying the MIAMOD method (a backward calculation approach using mortality and relative survival rates). Mortality data were obtained from the Ministry of Health and the relative survival rate for all gastrointestinal cancers combined was derived from the Eurocare 3 study. Results indicated that there were clear upward trends in age adjusted incidence (males 22.9 to 74.2 and females 14.9 to 44.2), prevalence (males 52.6 to 177.7 and females 38.3 to 111.03), and mortality (males 14.6 to 47.2 and females 9.6 to 28.2) rates per 100,000 for the period of 2001 to 2010 and this upward state would persist for the projected period. For the entire period, the male to female ratio increased slightly for all parameters (incidence rate increased from 1.5 to 1.7, prevalence from 1.4 to 1.6, and mortality from 1.5 to 1.7). In males, totals of 2,179 incident cases, 5,097 prevalent cases and 1,398 mortality cases were predicated to occur during the study period. For females the predicted figures were 1,379, 3,190 and 891, respectively. It was concluded that the upward trend of incidence alongside increase in survival rates would induce a high burden on the health care infrastructure in the province of Isfahan in the future.

Keywords

References

  1. Bray F, Moller B (2006). Predicting the future burden of cancer. Nat Rev Cancer, 6, 63-74. https://doi.org/10.1038/nrc1781
  2. Budroni M, Sechi O, Cossu A, et al (2013). Estimates of cancer burden in Sardinia. Tumori, 99, 408-15. https://doi.org/10.1177/030089161309900317
  3. De Angelis G, De Angelis R, Frova L, et al (1994). MIAMOD: a computer package to estimate chronic disease morbidity using mortality and survival data. Comput Methods Programs Biomed, 44, 99-107. https://doi.org/10.1016/0169-2607(94)90091-4
  4. De Vries AC, Kuipers EJ (2007). Review article: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther, 26, 25-35. https://doi.org/10.1111/j.1365-2036.2007.03475.x
  5. Dyba T, Hakulinen T (2000). Comparison of different approaches to incidence prediction based on simple interpolation techniques. Stat Med, 19, 1741-52. https://doi.org/10.1002/1097-0258(20000715)19:13<1741::AID-SIM496>3.0.CO;2-O
  6. Etemadi A, Sadjadi A, Semnani S, et al (2008). Cancer registry in Iran: a brief overview. Arch Iran Med, 11, 577-80.
  7. Ferlay J, Soerjomataram I, Ervik M, et al (2012). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality world wide: IRAC Cancer base NO.11 online. Available: http://globocan.iarc.fr/Pages/summarytablesitesel.aspx Accessed 10.29 2015.
  8. Foschi R, Viviano L, Rossi S (2013). Estimates of cancer burden in Abruzzo and Molise. Tumori, 99, 366-73. https://doi.org/10.1177/030089161309900312
  9. Fitzmaurice C, Dicker D, et al (2015). The Global Burden of Cancer 2013. JAMA Oncol, 1, 505-27. https://doi.org/10.1001/jamaoncol.2015.0735
  10. Grande E, Inghelmann R, Francisci S, et al (2007). Regional estimates of colorectal cancer burden in Italy. Tumori, 93, 352-9. https://doi.org/10.1177/030089160709300405
  11. Herszenyi L, Tulassay Z (2010). Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci, 14, 249-58.
  12. Hosseini SV, Izadpanah A, Yarmohammadi H (2004). Epidemiological changes in colorectal cancer in Shiraz, Iran: 1980-2000. Anz J Surg, 74, 547-9. https://doi.org/10.1111/j.1445-2197.2004.03064.x
  13. Inghelmann R, Grande E, Francisci S, et al (2007). Regional estimates of stomach cancer burden in Italy. Tumori, 93, 367-73. https://doi.org/10.1177/030089160709300407
  14. Jafari N, Kabir M, Motlagh M (2009). Death registration system in I.R.Iran. Iran J Public Health, 38, 127-9.
  15. Jensen OM, Storm HH (1991). Cancer registration: principles and methods. Reporting of results. IARC Sci Publ, 108-25.
  16. Joliat GR, Hahnloser D, Demartines N, et al (2015). Future development of gastrointestinal cancer incidence and mortality rates in Switzerland: a tumour registry- and population-based projection up to 2030. Swiss Med Wkly, 145, 141-88.
  17. Lieberman LS (2003). Dietary, evolutionary and modernizing influences on the prevalence of type 2 diabetes. Annu Rev Nutr, 23, 345-77. https://doi.org/10.1146/annurev.nutr.23.011702.073212
  18. Maracy MR, Moradpour F, Hosseini SM, et al (2012). Cancer incidence and prevalence in isfahan: application of mortality data to estimates and projects for the period 2001-2015. Int J Prev Med, 3, 867-74. https://doi.org/10.4103/2008-7802.104858
  19. Moradpour F, Fatemi Z (2013). Estimation of the projections of the incidence rates, mortality and prevalence due to common cancer site in Isfahan, Iran. Asian Pac J Cancer Prev, 14, 3581-5. https://doi.org/10.7314/APJCP.2013.14.6.3581
  20. Naghibzadeh Tahami A, Khanjani N, Yazdi Feyzabadi V, et al (2014). Opium as a risk factor for upper gastrointestinal cancers: a population-based case-control study in Iran. Arch Iran Med, 17, 2-6.
  21. Parkin DM (2006). The evolution of the population-based cancer registry. Nat Rev Cancer, 6, 603-12. https://doi.org/10.1038/nrc1948
  22. Rashid I, Pannozzo F, Rossi S, et al (2013). Estimates of cancer burden in Lazio. Tumori, 99, 359-65. https://doi.org/10.1177/030089161309900311
  23. Roazzi P, Capocaccia R, Santaquilani M, et al (2003). Electronic availability of EUROCARE-3 data: a tool for further analysis. Ann Oncol, 14, 150-5. https://doi.org/10.1093/annonc/mdg757
  24. Rodgers A, Ezzati M, Vander Hoorn S, et al (2004). Distribution of major health risks: findings from the Global Burden of Disease study. PLoS Med, 1, 27. https://doi.org/10.1371/journal.pmed.0010027
  25. Rossi S, Crocetti E, Capocaccia R, et al (2013). Estimates of cancer burden in Italy. Tumori, 99, 416-24. https://doi.org/10.1177/030089161309900318
  26. Sadjadi A, Nouraie M, Mohagheghi MA, et al (2005). Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev, 6, 359-63.
  27. Stuckler D (2008). Population causes and consequences of leading chronic diseases: a comparative analysis of prevailing explanations. Milbank Q, 86, 273-326. https://doi.org/10.1111/j.1468-0009.2008.00522.x
  28. Ventura L, Miccinesi G, Sacchettini C, et al (2012). Estimating all cancers incidence with the MIAMOD model: a new method to include multiple tumors. Tumori, 98, 296-302. https://doi.org/10.1177/030089161209800303
  29. Verdecchia A, Capocaccia R, Egidi V, et al (1989). A method for the estimation of chronic disease morbidity and trends from mortality data. Stat Med, 8, 201-16. https://doi.org/10.1002/sim.4780080207